Eisai Announces FDA Acceptance of NDA for the Review of FYCOMPAÂ® (perampanel) Oral Suspension for Adjunctive Therapy in the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures in Patients with